Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
- 
                
          Enhancers are short regions of2023-10-10  Enhancers are short regions of DNA that are bound by DNA-binding proteins (TFs) to increase the likelihood of a particular gene to be expressed. Importantly, enhancers can be identified, and classified, by their patterns of chromatin accessibility and of enrichment in certain histone modifications. 
- 
                
          Later on Wayner Burton Ingold Barclay and Locke2023-10-10  Later on, Wayner, Burton, Ingold, Barclay, and Locke (1987) modified the method by using lipid to examine the ability of an antioxidant taurolidine protect against lipid peroxidation generated by azo-compound. It was later improved using β-phycoerythrin (β-PE) as a fluorescent probe, and the abilit 
- 
                
          Most clinically approved antiangiogenic drugs are aimed at b2023-10-10  Most clinically approved antiangiogenic drugs are aimed at blocking the action of vascular endothelial growth factor, or VEGF, which is accepted to be the most important tumor-derived angiogenic factor, stimulating proliferation and migration of endothelial cells, as well as branching of vessels (Fe 
- 
                
          The excellent safety profile of solanezumab and encouraging2023-10-10  The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr 
- 
                
          The increased occurrence of ARIA2023-10-10  The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied 
- 
                
          Recent studies suggest that A caused2023-10-10  Recent studies suggest that Aβ caused synapse damage as a consequence of aberrant cell signalling. As synthetic Aβ42 monomers activate the phosphatidylinositol-3-kinase pathway (Giuffrida et al., 2009) and insulin signalling (Giuffrida et al., 2012) it is possible that Aβ monomers and Aβ oligomers a 
- 
                
          Interestingly we noticed that LPS exposure2023-10-10  Interestingly, we noticed that LPS exposure was associated with decreased phosphorylation of AMPK and increased phosphorylation of p70S6K1, suggesting that AMPK inactivation and the subsequent mTOR activation might be involved in the development of LPS-induced inflammation. On the other side, treatm 
- 
                
          br The lipoxygenase pathway in the pancreatic islet2023-10-10  The 12/15-lipoxygenase pathway in the pancreatic islet and in diabetes mellitus Homeostasis of blood glucose is maintained by hormone secretion from the pancreatic islets of Langerhans. More specifically, insulin produced by the β Phusion high-fidelity DNA polymerase synthesis of the islet plays 
- 
                
          br Introduction Diabetes mellitus DM is a chronic2023-10-10  Introduction Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated levels of glucose in the blood. Type 1 diabetes is characterized by insufficient insulin production and needs a daily administration of insulin. Actually, no prevention is known for Type 1 diabetes. Type 
- 
                
          The assay performance was estimated using Z2023-10-09  The assay performance was estimated using Z′-factors (plotted in Fig. 2A) according to Zhang et al. calculated for each plate comparing positive (in the absence of an inhibitor) and negative controls (in the presence of an AdK inhibitor). The mean Z′-factor±SD was determined to be 0.7±0.1, indicativ 
- 
                
          Inhibitors of mPGES are considered as2023-10-09  Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e 
- 
                
          br Autophagy and antiviral innate immunity signaling br Vira2023-10-09  Autophagy and antiviral innate immunity signaling Viral manipulation of autophagy interfering with IFN-I synthesis We have seen that autophagy factors can down-regulate the production of IFN-I induced by RLR engagement during viral infection. In fibroblasts and epithelial cells, there exists c 
- 
                
          Crohn s disease an inflammatory bowel disease that2023-10-09  Crohn’s disease, an inflammatory bowel disease that affects the gastrointestinal (GI) tract, is characterized by a polymorphism in ULK1 autophagy gene due to the presence of single nucleotide polymorphisms (SNPs). Thus, the autophagic process is impaired during the disease. The mutations in the leuc 
- 
                
          In the last decade the zebrafish has emerged as a2023-10-09  In the last decade, the zebrafish has emerged as a valuable vertebrate model to systematically dissect the genetic underpinnings of both vertebrate heart development and function [8,9], as well as distinct cardiac diseases such as congenital heart disease [10], cardiomyopathies [11,12] and cardiac a 
- 
                
          br Transparency document br Acknowledgments This work2023-10-09  Transparency document Acknowledgments This work has been supported by the National Eye Institute (NIH) Grant 5R01EY023315-02 (MA). This study was also supported in part by National Center for Research Resources Grant S10RR027926 for the lipid analysis and by James and Jean Culver Vision Discov 
14862 records 268/991 page Previous Next First page 上5页 266267268269270 下5页 Last page